Atria Wealth Solutions Inc. Has $226,000 Stock Holdings in Enovix Co. (NASDAQ:ENVX)

Atria Wealth Solutions Inc. reduced its holdings in shares of Enovix Co. (NASDAQ:ENVX) by 14.4% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 18,035 shares of the company’s stock after selling 3,030 shares during the period. Atria Wealth Solutions Inc.’s holdings in Enovix were worth $226,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Allspring Global Investments Holdings LLC bought a new stake in shares of Enovix in the 3rd quarter valued at approximately $31,000. Beacon Capital Management LLC raised its stake in Enovix by 66.7% during the fourth quarter. Beacon Capital Management LLC now owns 2,500 shares of the company’s stock worth $31,000 after acquiring an additional 1,000 shares in the last quarter. Carmel Capital Partners LLC bought a new position in shares of Enovix during the third quarter valued at $34,000. Cidel Asset Management Inc. acquired a new stake in shares of Enovix in the 3rd quarter valued at $131,000. Finally, B. Riley Wealth Advisors Inc. bought a new stake in shares of Enovix in the 3rd quarter worth about $133,000. Institutional investors own 50.92% of the company’s stock.

Analysts Set New Price Targets

ENVX has been the topic of a number of recent analyst reports. William Blair restated an “outperform” rating on shares of Enovix in a research report on Thursday, May 2nd. B. Riley dropped their price target on Enovix from $18.00 to $16.00 and set a “buy” rating for the company in a report on Tuesday, April 30th. Cantor Fitzgerald reissued an “overweight” rating and issued a $30.00 price objective on shares of Enovix in a research note on Thursday, April 25th. Canaccord Genuity Group restated a “buy” rating and set a $17.00 target price on shares of Enovix in a report on Wednesday, February 21st. Finally, JPMorgan Chase & Co. cut their price target on Enovix from $18.00 to $12.00 and set an “overweight” rating for the company in a report on Friday, April 26th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $18.33.

Insider Buying and Selling

In other Enovix news, COO Ajay Marathe sold 4,954 shares of Enovix stock in a transaction on Sunday, April 14th. The shares were sold at an average price of $7.31, for a total transaction of $36,213.74. Following the completion of the sale, the chief operating officer now owns 978,913 shares of the company’s stock, valued at approximately $7,155,854.03. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 17.30% of the stock is currently owned by insiders.

Enovix Stock Up 0.7 %

NASDAQ ENVX opened at $9.14 on Friday. The company has a debt-to-equity ratio of 0.65, a quick ratio of 5.15 and a current ratio of 5.30. Enovix Co. has a 52 week low of $5.70 and a 52 week high of $23.90. The stock has a market capitalization of $1.55 billion, a P/E ratio of -6.82 and a beta of 1.70. The stock has a fifty day moving average of $7.84 and a 200-day moving average of $9.98.

Enovix (NASDAQ:ENVX) last announced its quarterly earnings data on Tuesday, February 20th. The company reported ($0.35) EPS for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.01). Enovix had a negative return on equity of 83.66% and a negative net margin of 1,448.90%. The firm had revenue of $7.38 million during the quarter, compared to analyst estimates of $3.37 million. On average, equities research analysts forecast that Enovix Co. will post -1.13 EPS for the current year.

Enovix Company Profile

Enovix Corporation designs, develops, and manufactures lithium-ion batteries. It serves wearables and IoT, smartphone, laptops and tablets, industrial and medical, and electric vehicles industries. The company was founded in 2007 and is headquartered in Fremont, California.